| Non-Small Cell Lung Carcinoma

Tafinlar + Mekinist vs Zirabev

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.

Deep comparison between: Tafinlar vs Zirabev with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZirabev has a higher rate of injection site reactions vs Tafinlar based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zirabev but not Tafinlar, including UnitedHealthcare

Category

Tafinlar

Zirabev

At A Glance

RouteOral

FrequencyTwice daily

ClassBRAF kinase inhibitor

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassVEGF inhibitor

Indications

melanoma
Non-Small Cell Lung Carcinoma
Anaplastic thyroid carcinoma
Low grade glioma
Solid Neoplasm

Metastasis from malignant neoplasm of colon and/or rectum
Non-Small Cell Lung Carcinoma
Glioblastoma
Renal Cell Carcinoma
Cervix carcinoma
Malignant neoplasm of ovary
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Dosing

Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.

Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.

Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.

Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.

Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.

Metastasis from malignant neoplasm of colon and/or rectum 5 mg/kg IV every 2 weeks with bolus-IFL; 10 mg/kg IV every 2 weeks with FOLFOX4; 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen.

Non-Small Cell Lung Carcinoma 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma 10 mg/kg IV every 2 weeks.

Renal Cell Carcinoma 10 mg/kg IV every 2 weeks in combination with interferon alfa.

Cervix carcinoma 15 mg/kg IV every 3 weeks in combination with paclitaxel and cisplatin or paclitaxel and topotecan.

Malignant neoplasm of ovary, Fallopian Tube Carcinoma, Primary Peritoneal Cancer Stage III/IV following initial surgical resection: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent for up to 22 cycles. Platinum-resistant recurrent: 10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg IV every 3 weeks with topotecan (every 3 weeks). Platinum-sensitive recurrent: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel or carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent.

Contraindications

—

Drug Interactions

1301View drug interactions

231View drug interactions

Adverse Reactions

Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform

Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis

Most common (>10%) Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.

Serious Gastrointestinal perforations and fistulae, surgery and wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, renal injury and proteinuria, infusion-related reactions, ovarian failure, congestive heart failure.

Postmarketing Polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer, intestinal necrosis, anastomotic ulceration, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms/dissections/rupture.

Pharmacology

Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.

Bevacizumab-bvzr binds VEGF and prevents its interaction with receptors Flt-1 and KDR on the surface of endothelial cells, inhibiting endothelial cell proliferation, new blood vessel formation, and metastatic disease progression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Tafinlar